Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model

Journal of Pharmacological Sciences

Volumn 103, Issue 3, 2007, Pages 329-332

  Matsuya, Takahiro ^a,b   Takuma, Kazuhiro ^a   Sato, Kosuke ^a   Asai, Makoto ^b   Murakami, Yoshihiro ^b   Miyoshi, Sosuke ^b   Noda, Akihiro ^b   Nagai, Taku ^a   Mizoguchi, Hiroyuki ^a   Nishimura, Shintaro ^b   Yamada, Kiyofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Medical and Pharmacological Research Center Foundation   (Japan)

Author keywords

Adenosine A2A receptor; hemi Parkinsonian mouse model; L DOPA

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; APOMORPHINE; BENSERAZIDE; CYCLOPENTYL 1,3 DIPROPYLXANTHINE; FLAVINE MONONUCLEOTIDE; LEVODOPA; OXIDOPAMINE; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL MODEL; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RECEPTOR BLOCKING;

EID: 33947505232     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.SCZ070058     Document Type: Article

References (15)

1. Smith Y, Kieval JZ. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 2000;23:S28-S33.
2. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci. 2005;26:391-397.
3. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol. 2000;162:321-327.
4. 2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse. 2002;46:251-257.
5. 2A receptors. Prog Neurobiol. 1999;59:355-396.
6. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003;278:46741-46749.
7. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006;29:647-654.
8. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 1990;4:2737-2744.
9. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res. 2005;162:1-10.
10. 11C]SCH442416. Eur J Nucl Med Mol Imaging. 2005;32:405-413.
11. 2A receptor. J Mol Neurosci. 2004;24:173-180.
12. olf is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem. 2001;76:1585-1588.
13. 2 dopamine receptors. J Neurochem. 1994;62:411-420.
14. 2A receptor mRNA by dopamine denervation. Eur J Pharmacol. 2002;446:75-82.
15. 2A receptor mRNA expression in Parkinson's disease. Neurosci Lett. 2000;291:54-58.